Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies (Q34590400)

3 August 2017

Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies (English)

1 reference

3 August 2017

5

1 reference

3 August 2017

Sridhar Natesan

1

1 reference

3 August 2017

Greg E Reckless

series ordinal

2

1 reference

3 August 2017

Karen B L Barlow

series ordinal

3

1 reference

3 August 2017

José N Nobrega

series ordinal

4

1 reference

3 August 2017

language of work or name

English

0 references

publication date

13 December 2006

1 reference

3 August 2017

Neuropsychopharmacology

1 reference

3 August 2017

32

1 reference

3 August 2017

7

1 reference

3 August 2017

1540-1549

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.npp.1301279

3 August 2017

0 references

cites work

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

M1 muscarinic acetylcholine receptors activate extracellular signal-regulated kinase in CA1 pyramidal neurons in mouse hippocampal slices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Clozapine: efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Muscarinic receptors as a target for drugs treating schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Muscarinic mechanisms of antipsychotic atypicality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Potential role of muscarinic receptors in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: The nucleus accumbens shell as a locus of antipsychotic action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Activation of c-fos in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Noradrenaline reuptake inhibition enhances the antipsychotic-like effect of raclopride and potentiates D2-blockage-induced dopamine release in the medial prefrontal cortex of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Predictors of clinical outcome in schizophrenic patients responding to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

In vivo binding to dopamine receptors: a correlate of potential antipsychotic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- d -aspartate receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Antipsychotic action of selective group II metabotropic glutamate receptor agonist MGS0008 and MGS0028 on conditioned avoidance responses in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Enhancement of antipsychotic-like effects by combined treatment with the alpha1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Distribution of clozapine and desmethylclozapine between blood and brain in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Effects of desmethylclozapine on Fos protein expression in the forebrain: in vivo biological activity of the clozapine metabolite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: a comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

7 January 2021

Tissue concentrations of clozapine and its metabolites in the rat

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

7 January 2021

Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

7 January 2021

Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

7 January 2021

Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

7 January 2021

Evidence for specific interactions between 5-HT1A and dopamine D2 receptor mechanisms in the mediation of extrapyramidal motor functions in the rat

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301279

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1301279

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference